Abstract: Objective To study the relative risk factors of adverse reactions for improving the application security and expanding the range of irinotecan. Methods Patients were collected and analyzed on adverse reactions in the oncology of our hospital from December 2011 to October 2012, who are using irinotecan combination chemotherapy.Fisher accurate inspection was adopted in SPSS17.0, and analyzed the relations between different kinds of clinical parameters with adverse reactions. Results The incidence of nausea and vomiting was 64.00%. The incidence of severe nausea and vomiting (Ⅲdegrees) was 8.00%.The incidence of bone marrow suppression was 56.00%. Severe bone marrow suppression(above Ⅲdegrees) incidence was 12.00%. Delayed diarrhea incidence was 40.00%. Severe diarrhea (Ⅲdegrees) incidence was 4.00%, no more serious diarrhoea(Ⅳdegree).Acute cholinergic syndrome incidence was 16.00%. Long-term smoking and alcohol drinking history were risk factors of diarrhea. Conclusion The adverse reactions of irinotecan are more common, but severe bone marrow suppression and delayed diarrhea (Ⅲ-Ⅳdegree) with low incidence. Delayed diarrhea occurred around the time of 4～6 days after medication. The patients had delayed diarrhea occurred at higher risk with a long history of cigarette smoking and alcohol drinking. This part of patients should be reinforced of cigarette and alcohol abstinence promotion to achieve the safety.

Key words: Irinotecan, colorectal cancer, adverse reactions